H.C. Wainwright's Crypto & Digital Infrastructure Highlights from our 28th Annual Global Investment Conference are now available. Read the full report: hcwco-portal.bluematrix.com/…

H.C. Wainwright's Life Sciences Highlights from our 28th Annual Global Investment Conference are now available. Read the full report: hcwco-portal.bluematrix.com/…

𝐇𝐂𝐖 𝟐𝟎𝟐𝟔: @HCWCO Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology. $VSTM $IMRX $CGON $CADL Full video: biotechtv.com/post/andres-ma…

Congratulations to the team at @Precigen on receiving the FDA's platform technology designation for its AdenoVerse immunotherapeutic platform. H.C. Wainwright's Swayampakula Ramakanth, Ph.D. discusses the designation: hcwco-portal.bluematrix.com/…

H.C. Wainwright is acting as Financial Advisor to Lisata Therapeutics, Inc. (@lisata_tx) on their acquisition of Marea Therapeutics (@Marea_tx). This post is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Thank you to everyone who joined us at our 28th Annual Global Investment Conference. This year, more than 2,500 attendees joined us, representing approximately 520 companies across all sectors, both in person and virtually. This included over 250 public life sciences companies represented in person and 900+ healthcare investors. Together, they took part in more than 2,600 one-on-one meetings. Thank you to our sponsors, speakers, and attendees for making this year's conference a success. We are already looking forward to next year.

𝐇𝐂𝐖 𝟐𝟎𝟐𝟔: @HCWCO Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech. Full video: biotechtv.com/post/richard-g…

The Investment Case for Digital Asset Treasury Companies Panel is about to begin. Watch the Panel: ct.to/BTCETH Panelists: @SamirTabar, CEO, @BitDigital_BTBT (Nasdaq: BTBT) @Charles_BTCS, Chairman & CEO, @NasdaqBTCS (Nasdaq: BTCS) @BenPhiat, CFO, @Strive Inc. (Nasdaq: ASST) This panel will examine the investment case for digital asset treasury companies, including capital formation, valuation relative to net asset value, digital asset growth on a per-share basis, capital structure, liquidity, governance, staking and the potential to create sustainable shareholder value.

𝐇𝐂𝐖 𝟐𝟎𝟐𝟔: @HCWCO's Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while. Full video: biotechtv.com/post/james-cap…

Join us for a livestream panel today at 2:30pm ET at @HCWCO's 28th Annual Global Investment Conference The Investment Case for Digital Asset Treasury Companies Panelists: @SamirTabar - CEO @BitDigital_BTBT @Charles_BTCS - Chairman & CEO @NasdaqBTCS @BenPhiat - CFO @Strive Register here: journey.ct.events/view/19a93…

Catch BTCS CEO @Charles_BTCS live today at 2:30pm ET. He'll be speaking on a panel at the @HCWCO's 28th Annual Global Investment Conference, alongside @SamirTabar and @BenPhiat. Register to watch here: journey.ct.events/view/19a93…

Hear from HCW analysts, Raghuram Selvaraju, PhD, MBA and Mitchell Kapoor, who published their inaugural market sentiment analysis of clinical readouts, a study of 568 trial results from January 2025 through September 10, 2026. The data show a more receptive market heading into year-end, with immunology & inflammation delivering the most consistent gains and select oncology programs offering breakthrough-scale upside. Read the full report here: lnkd.in/gyktzW_Q

We are officially less than an hour away from our upcoming panel: Powering the AI Boom & Bitcoin Network: The Digital Infrastructure Companies Leading the Charge. The panel will examine how leading digital infrastructure companies are securing and developing power, financing new capacity and allocating infrastructure across AI, high-performance computing and Bitcoin workloads. The discussion will also address data-center development, customer demand, capital intensity and power economics. Panelists: @kilgore_joshua, Executive Chairman, @BigDigital (Nasdaq: BGDE) Michael Potter, CFO, @Bitdeer Technologies Group (Nasdaq: BTDR) @smatthewschultz, Chairman & CEO, @CleanSpark_Inc, Inc. (Nasdaq: CLSK) @russellcann, Chief Development Officer, @Core_Scientific (Nasdaq: CORZ) @fgthiel, Chairman & CEO, @MARA Holdings, Inc. (Nasdaq: MARA) @jbelizaireCEO, CEO, @SolunaHoldings (Nasdaq: SLNH) @SamirTabar, CEO, @WhiteFiber_, (Nasdaq: WYFI) The panel will be moderated by Mike Colonnese, CFA, Head of Crypto & Digital Infrastructure Equity Research at H.C. Wainwright. Watch the panel: ct.to/AIBc26

Our 28th Annual Global Investment Conference kicked off today at the Lotte New York Palace Hotel, starting with our Most Favored Drug Pricing panel moderated by Douglas Tsao, Managing Director, Senior Biotechnology Equity Research Analyst, and Ananda Ghosh, PhD, Senior Biotechnology Equity Research Analyst. Joined by James C. Robinson, Leonard D. Schaeffer Distinguished Professor of Health Economics, University of California Berkeley, the panel discussed whether the Most Favored Nation drug pricing represents political theater or reflects underlying challenges facing the drug industry in terms of political pressure on US drug prices, erosion of the EU innovation ecosystem, the role of higher prices to support it, and the rise of China. Access the replay: ct.to/drugcst

Bit Digital and WhiteFiber CEO @SamirTabar will be joining @HCWCO's panel today at 2:00pm ET to discuss data center development, how infrastructure companies are securing and developing power, financing new capacity, and allocating infrastructure across AI and HPC.

H.C. Wainwright is excited to announce our upcoming life science panels to take place at our 28th Annual Global Investment Conference. These panels will bring together leaders across drug pricing policy, capital markets, FDA regulatory strategy, pharmacy distribution, and precision oncology research. Most Favored Nation Drug Pricing: Political Theatre or Existential Challenge? Monday, September 14, 2026, at 8:00 a.m. ET The panel will be moderated by Douglas Tsao, H.C. Wainwright Managing Director, Senior Biotechnology Equity Research Analyst and Ananda Ghosh, PhD, Senior Biotechnology Equity Research Analyst. Panelist: James C. Robinson (Leonard D. Schaeffer Distinguished Professor of Health Economics, University of California Berkeley) Watch the Panel: ct.to/drugcst Life Sciences Capital Markets Update Monday, September 14, 2026, at 8:50 a.m. ET The discussion will be led by Richard Gormley, H.C. Wainwright Vice Chairman and President of Capital Markets. Watch the Session: ct.to/cmu26 FDA's Evolving Stance On Artificial Intelligence Monday, September 14, 2026, at 11:00 a.m. ET The panel will be moderated by Swayampakula Ramakanth, Ph.D., H.C. Wainwright Managing Director, Senior Biotechnology Equity Research Analyst. Panelists: Kalah Auchincloss, JD, MPH (Co-Founder, President & Principal, Canal Row Advisors) Hilary Marston, M.D., MPH (Principal, Canal Row Advisors) Watch the Panel: ct.to/FDAAI26 Current Pharmacy Market Trends And The Issues Impacting Them Tuesday, September 15, 2026, at 8:00 a.m. ET The panel will be moderated by Douglas Tsao, H.C. Wainwright Managing Director, Senior Biotechnology Equity Research Analyst. Panelist: Scott Biggs, (Director of Supplier Services, IQVIA) Watch the Panel: ct.to/PharmTz Oncology Beyond IO: The Next Wave Of Targeted, Engineered, And Precision Therapeutics Tuesday, September 15, 2026, at 11:00 a.m. ET The panel will be moderated by Andres Y. Maldonado Ph.D., H.C. Wainwright Senior Biotechnology Equity Research Analyst. Panelists: Piro Lito, M.D., Ph.D., (Enid A Haupt Chair in Therapeutic Research, Professor and Member Memorial Sloan Kettering Cancer Center) Thomas U. Marron, M.D., Ph.D. (Professor of Medicine, Hematology, & Oncology, Tisch Cancer Center Icahn School of Medicine at Mount Sinai) Watch the Panel: ct.to/OncIO26

H.C. Wainwright Analyst Mitchell Kapoor examines what Novartis's HORIZON and Novo Nordisk's ZEUS trial misses mean for the cardiovascular space. In his view, the setback reinforces the case for several validated approaches within our coverage. 🔗 Read the full report from Mitchell Kapoor and Raghuram Selvaraju to learn more about the validated approaches this reinforces: hcwco-portal.bluematrix.com/…

Join us next week at H.C. Wainwright's 28th Annual Global Investment Conference in NYC! Panel 1: Powering the AI Boom & Bitcoin Network: The Digital Infrastructure Companies Leading the Charge Monday, 9/14 @ 2:00 p.m. ET Panel 2: The Investment Case for Digital Asset Treasury Companies Tuesday, 9/15 @ 2:30 p.m. ET

H.C. Wainwright is excited to announce our upcoming panels to take place at our 28th Annual Global Investment Conference. These panels will bring together senior executives across AI and high-performance computing infrastructure, data centers, power, Bitcoin mining and digital asset treasury companies. Both panels will be moderated by Mike Colonnese, CFA, Head of Crypto & Digital Infrastructure Equity Research at H.C. Wainwright. Powering the AI Boom & Bitcoin Network: The Digital Infrastructure Companies Leading the Charge Monday, September 14, 2026, at 2:00 p.m. ET The panel will examine how leading digital infrastructure companies are securing and developing power, financing new capacity and allocating infrastructure across AI, high-performance computing and Bitcoin workloads. The discussion will also address data-center development, customer demand, capital intensity and power economics. Panelists: @kilgore_joshua, Executive Chairman, @BigDigital, (Nasdaq: BGDE) Michael Potter, CFO, @Bitdeer (NASDAQ: BTDR) Technologies Group @smatthewschultz, Chairman & CEO, @CleanSpark_Inc (Nasdaq: CLSK) @russellcann, Chief Development Officer, @Core_Scientific (Nasdaq: CORZ) @fgthiel, Chairman & CEO, @MARA Holdings, Inc. (Nasdaq: MARA) @jbelizaireCEO, CEO, @SolunaHoldings (Nasdaq: SLNH) @SamirTabar, CEO, @WhiteFiber_ (Nasdaq: WYFI) The Investment Case for Digital Asset Treasury Companies Tuesday, September 15, 2026, at 2:30 p.m. ET The panel will examine the investment case for digital asset treasury companies, including capital formation, valuation relative to net asset value, digital asset growth on a per-share basis, capital structure, liquidity, governance, staking and the potential to create sustainable shareholder value. Panelists: @SamirTabar, CEO, @BitDigital_BTBT @Charles_BTCS, Chairman & CEO, @NasdaqBTCS (Nasdaq: BTCS) @BenPhiat, CFO, @Strive (Nasdaq: ASST) Watch the Panel: ct.to/BTCETH